2. Search Result
Search Result
Results for "

Ischemic injury

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

6

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-143333
    Nrf2 activator-3

    		Keap1-Nrf2 Neurological Disease Inflammation/Immunology
    Nrf2 activator-3 is a potent Nrf2 activator. Nrf2 activator-3 is used for cerebral ischemic injury research .
    Nrf2 activator-3
  • HY-109097
    Otaplimastat

    SP-8203

    		 MMP iGluR Neurological Disease
    Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury .
    Otaplimastat
  • HY-149967
    GluN2B-NMDAR antagonist-1

    		iGluR Neurological Disease Inflammation/Immunology
    GluN2B-NMDAR antagonist-1 is an orally active GluN2B-NMDAR antagonist. GluN2B-NMDAR antagonist-1 has neuroprotective activity. GluN2B-NMDAR antagonist-1 can be used for research of ischemic injury .
    GluN2B-NMDAR antagonist-1
  • HY-116444
    16(S)-HETE

    		Others Neurological Disease
    16(S)-HETE is an endogenous inhibitor of neutrophil activity and can be used in the study of acute ischemic brain injury .
    16(S)-HETE
  • HY-P5754
    TAT-NEP1-40

    		Apoptosis Neurological Disease
    TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .
    TAT-NEP1-40
  • HY-P1061
    Colivelin
    Maximum Cited Publications
    37 Publications Verification

    		 STAT Amyloid-β Neurological Disease
    Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
    Colivelin
  • HY-P5754A
    TAT-NEP1-40 TFA

    		Apoptosis Neurological Disease
    TAT-NEP1-40 TFA is a BBB-penatrable peptide. TAT-NEP1-40 TFA protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 TFA also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 TFA can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke .
    TAT-NEP1-40 TFA
  • HY-P1061A
    Colivelin TFA
    Maximum Cited Publications
    37 Publications Verification

    		 STAT Amyloid-β Apoptosis Neurological Disease
    Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .
    Colivelin TFA
  • HY-132845
    Utreloxastat

    PTC857

    		 α-synuclein Neurological Disease
    Utreloxastat (PTC857) is a compound used for the research of the disorders including α-synucleinopathies, tauopathies, Amyotrophic lateral sclerosis (ALS), traumatic brain injury, and ischemic-reperfusion related injuries (patent WO2020081879A2, example A1) .
    Utreloxastat
  • HY-148226
    20-5,14-HEDGE

    		Others Cardiovascular Disease
    20-5,14-HEDGE is a 20-HETE analog. 20-5,14-HEDGE protects against lung ischemic reperfusion injury in rats .
    20-5,14-HEDGE
  • HY-112248A
    HAMI 3379

    		Leukotriene Receptor Cardiovascular Disease Inflammation/Immunology
    HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation .
    HAMI 3379
  • HY-N4098
    Incensole Acetate

    		Apoptosis Neurological Disease
    Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .
    Incensole Acetate
  • HY-106592A
    U-74389G

    PNU74389G (meleate)

    		 Others Others
    U-74389G (PNU74389G meleate) is an antioxidant, can inhibit lipid peroxidation reactions. U-74389G can protect against ischemia-reperfusion injury and be widely used in animal models of ischemic injury and hypertension. U-74389G shows anti-inflammatory activity .
    U-74389G
  • HY-153977
    GLX481304

    		NADPH Oxidase Cardiovascular Disease
    GLX481304 is a specific inhibitor of Nox-2 and -4, with IC50s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart .
    GLX481304
  • HY-N3239
    Mulberrofuran G

    		NADPH Oxidase HBV
    Mulberrofuran G protects ischemic injury-induced cell death via inhibition of NOX4-mediated ROS generation and ER stress . Mulberrofuran G shows moderate inhibiting activity of hepatitis B virus (HBV) DNA replication with IC50 of 3.99 μM .
    Mulberrofuran G
  • HY-105692
    DR2313

    		PARP Neurological Disease
    DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo .
    DR2313
  • HY-17369
    Tirofiban hydrochloride monohydrate
    1 Publications Verification

    L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate

    		 Integrin Cardiovascular Disease
    Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban hydrochloride monohydrate
  • HY-17369B
    Tirofiban
    1 Publications Verification

    L700462; MK383

    		 Integrin Cardiovascular Disease
    Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban
  • HY-17369A
    Tirofiban hydrochloride

    L700462 hydrochloride; MK383 hydrochloride

    		 Integrin Cardiovascular Disease
    Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban hydrochloride
  • HY-120327
    KY-226
    1 Publications Verification

    		 Phosphatase Neurological Disease Metabolic Disease
    KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .
    KY-226
  • HY-139598
    LFHP-1c

    		Phospholipase Cardiovascular Disease
    LFHP-1c is an PGAM5 inhibitor with neuroprotective activity in brain ischemic stroke. LFHP-1c protects blood-brain barrier integrity from ischemia-induced injury. LFHP-1c binds to endothelial PGAM5 to inhibit the activity of PGAM5 phosphatase and the interaction of PGAM5 with NRF2. LFHP-1c exhibits in vitro and in vivo protection .
    LFHP-1c
  • HY-N8931
    Monomethyl lithospermate

    Lithospermic acid monomethyl ester

    		 Akt Neurological Disease
    Monomethyl lithospermate activates the PI3K/AKT pathway, which plays a protective role in nerve injury. Monomethyl lithospermate can improve the survival ability of SHSY-5Y cells, inhibit the breakdown of mitochondrial membrane potential (MMOP) and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of rats with middle artery occlusion (MCAO) and improved nerve damage in rats with ischemic stroke (IS) .
    Monomethyl lithospermate
  • HY-115460
    AER-271

    		Aquaporin Cardiovascular Disease Neurological Disease
    AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke .
    AER-271
  • HY-100206
    5α-Androstane-3β,5,6β-triol

    		AMPK Neurological Disease
    5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo .
    5α-Androstane-3β,5,6β-triol
  • HY-126049
    (S)-Oxiracetam

    (S)-(-)-Oxiracetam; (S)-ISF2522

    		 Apoptosis Neurological Disease
    (S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .
    (S)-Oxiracetam
  • HY-B0378A
    Moexipril hydrochloride

    RS-10085

    		 Angiotensin-converting Enzyme (ACE) Apoptosis Cardiovascular Disease
    Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects - .
    Moexipril hydrochloride
  • HY-117281
    Moexipril

    		Angiotensin-converting Enzyme (ACE) Apoptosis Cardiovascular Disease Neurological Disease
    Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril exhibits antihypertensive and neuroprotective effects - .
    Moexipril
  • HY-117281S1
    Moexipril-d3

    		Apoptosis Angiotensin-converting Enzyme (ACE) Isotope-Labeled Compounds Cardiovascular Disease Neurological Disease
    Moexipril-d3 is deuterated labeled Moexipril (HY-117281). Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila hydrochloride. Moexipril exhibits antihypertensive and neuroprotective effects - .
    Moexipril-d3
  • HY-P5117
    TAT-CIRP

    		Toll-like Receptor (TLR) Neurological Disease
    TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice .
    TAT-CIRP
  • HY-107666
    PHA 568487

    		nAChR Neurological Disease Inflammation/Immunology
    PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR) .PHA 568487 reduces neuroinflammation and oxidative stress . PHA-568487 has rapid brain penetration .
    PHA 568487

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: